Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Liver Cancer Immunity.

Literature DB >> 32516437

Liver Cancer Immunity.

Sumera Rizvi¹, Juan Wang¹, Anthony B El-Khoueiry².

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2020 PMID： 32516437 PMCID： PMC8218340 DOI： 10.1002/hep.31416

Source DB: PubMed Journal: Hepatology ISSN： 0270-9139 Impact factor: 17.425

× No keyword cloud information.

61 in total

1. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.

Authors: Chi Ma; Miaojun Han; Bernd Heinrich; Qiong Fu; Qianfei Zhang; Milan Sandhu; David Agdashian; Masaki Terabe; Jay A Berzofsky; Valerie Fako; Thomas Ritz; Thomas Longerich; Casey M Theriot; John A McCulloch; Soumen Roy; Wuxing Yuan; Vishal Thovarai; Shurjo K Sen; Mathuros Ruchirawat; Firouzeh Korangy; Xin Wei Wang; Giorgio Trinchieri; Tim F Greten
Journal: Science Date: 2018-05-25 Impact factor: 47.728

2. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.

Authors: Zexin Lin; Yilin Yang; Yongliang Huang; Junjie Liang; Fang Lu; Xuejun Lao
Journal: Mol Clin Oncol Date: 2015-05-15

Review 3. Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors: Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal: Cancer Cell Date: 2015-04-06 Impact factor: 31.743

4. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents.

Authors: Le-Xing Yu; He-Xin Yan; Qiong Liu; Wen Yang; Hong-Ping Wu; Wei Dong; Liang Tang; Yan Lin; Ya-Qin He; Shan-Shan Zou; Chao Wang; Hui-Lu Zhang; Guang-Wen Cao; Meng-Chao Wu; Hong-Yang Wang
Journal: Hepatology Date: 2010-10 Impact factor: 17.425

Review 5. The role of myeloid cells in cancer therapies.

Authors: Camilla Engblom; Christina Pfirschke; Mikael J Pittet
Journal: Nat Rev Cancer Date: 2016-07 Impact factor: 60.716

6. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Authors: Bruno Sangro; Carlos Gomez-Martin; Manuel de la Mata; Mercedes Iñarrairaegui; Elena Garralda; Pilar Barrera; Jose Ignacio Riezu-Boj; Esther Larrea; Carlos Alfaro; Pablo Sarobe; Juan José Lasarte; Jose L Pérez-Gracia; Ignacio Melero; Jesús Prieto
Journal: J Hepatol Date: 2013-03-04 Impact factor: 25.083

Review 7. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.

Authors: Chiara Raggi; Pietro Invernizzi; Jesper B Andersen
Journal: J Hepatol Date: 2014-09-16 Impact factor: 25.083

8. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.

Authors: Maider Zabala; Juan José Lasarte; Christine Perret; Josu Sola; Pedro Berraondo; Maite Alfaro; Esther Larrea; Jesús Prieto; M Gabriela Kramer
Journal: J Hepatol Date: 2007-10-01 Impact factor: 25.083

9. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.

Authors: Yuki Kitano; Hirohisa Okabe; Yo-Ichi Yamashita; Shigeki Nakagawa; Yoichi Saito; Naoki Umezaki; Masayo Tsukamoto; Takanobu Yamao; Kensuke Yamamura; Kota Arima; Takayoshi Kaida; Tatsunori Miyata; Kosuke Mima; Katsunori Imai; Daisuke Hashimoto; Yoshihiro Komohara; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal: Br J Cancer Date: 2017-11-09 Impact factor: 7.640

10. Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma.

Authors: Mariko Tsukagoshi; Satoshi Wada; Takehiko Yokobori; Bolag Altan; Norihiro Ishii; Akira Watanabe; Norio Kubo; Fumiyoshi Saito; Kenichiro Araki; Hideki Suzuki; Yasuo Hosouchi; Hiroyuki Kuwano
Journal: Cancer Sci Date: 2016-02-02 Impact factor: 6.716

16 in total

1. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.

Authors: Jie Wei; Da Lang Fang; Weijie Zhou; Yong Fei He
Journal: J Gastrointest Oncol Date: 2021-08

2. A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Authors: Wenmin Hu; Yongmei Shi; Tongqin Han; Caiyun Liu; Xipeng Cao; Guangjun Shi; Wenjing Zhu
Journal: Front Genet Date: 2022-05-03 Impact factor: 4.772

3. CD74⁺ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma.

Authors: Nan Xiao; Kangshuai Li; Xiaodong Zhu; Bin Xu; Xuefeng Liu; Ming Lei; Hui-Chuan Sun
Journal: Cancer Immunol Immunother Date: 2021-05-19 Impact factor: 6.968

4. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.

Authors: Yanan Peng; Chang Liu; Mengting Li; Wenjie Li; Mengna Zhang; Xiang Jiang; Ying Chang; Lan Liu; Fan Wang; Qiu Zhao
Journal: Cancer Cell Int Date: 2021-02-10 Impact factor: 5.722

5. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.

Authors: Zhuomao Mo; Daiyuan Liu; Dade Rong; Shijun Zhang
Journal: Front Immunol Date: 2021-02-17 Impact factor: 7.561

6. Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway.

Authors: Cuiju Wang; Yalei Lv; Ziyue Sha; Jingjing Zhang; Jianhua Wu; Yixin Qi; Zhanjun Guo
Journal: J Hepatocell Carcinoma Date: 2021-12-29

Review 10. Therapy of Primary Liver Cancer.

Authors: Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu
Journal: Innovation (Camb) Date: 2020-08-10